Gorlin syndrome, also known as basal cell nevus syndrome, is an inherited genetic disorder characterized by multiple basal cell skin cancer. The common symptoms observed during Gorlin syndrome are calcium deposition in brain, jaw cysts, skeletal changes and developmental disability. The person with Gorlin syndrome appears with a prominent forehead, widely spaced eyes, small skin bumps and skin cysts.
Gorlin syndrome is screened by neurological evaluation, dental X-Ray and measurement of head size. The main treatment for Gorlin syndrome includes imiquimod cream, chemotherapy, photodynamic therapy and retinoids. Ascend Biopharmaceuticals Ltd. is in the process of developing ASN-002, a chemoimmunotherapy, for the treatment of Gorlin syndrome. PellePharm Inc., and F. Hoffmann-La Roche Ltd. are some other key players having drugs for Gorlin syndrome in their pipeline.
Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1113
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
This post was originally published on Crypto Coin Guardian